Core Insights - LeMaitre Vascular, Inc. reported strong Q4 2025 results with a 16% increase in sales and a 47% increase in operating income, driven by growth in international markets and higher average selling prices [1][4][3] Financial Performance - Q4 2025 sales reached $64.5 million, a 16% increase compared to Q4 2024, with organic growth of 15% [9][22] - Gross margin improved to 71.7%, up 240 basis points, due to higher average selling prices and manufacturing efficiencies [3][9] - Operating income for Q4 was $18.8 million, reflecting a 47% increase, with operating expenses growing moderately by 6% [3][9] - Diluted EPS for Q4 was $0.68, a 39% increase year-over-year [21] Sales Growth Drivers - Key product categories contributing to sales growth included grafts (+27%), valvulotomes (+20%), and carotid shunts (+18%) [3] - Regional sales growth was notable, with EMEA sales increasing by 29%, APAC by 20%, and the Americas by 10% [3] Guidance and Future Outlook - For Q1 2026, the company expects sales between $65.6 million and $67.6 million, representing an 11% increase [4] - Full-year 2026 guidance anticipates sales of $280 million, a 12% increase, and operating income of $77.8 million, a 21% adjusted increase [4] - The company plans to maintain a gross margin of 72.1% for 2026 [4] Dividend and Share Repurchase - The Board of Directors approved a 25% increase in the quarterly dividend to $0.25 per share, payable on March 26, 2026 [6] - A share repurchase program was authorized for up to $100 million, set to conclude on February 18, 2027, unless extended [7]

Company Overview - LeMaitre Vascular, Inc. (NASDAQ:LMAT) is a medical device company focused on products for peripheral vascular disease, which affects over 200 million people globally [2] - The company develops and markets a range of disposable and implantable devices for vascular surgeons, including biologic and biosynthetic grafts, embolectomy and thrombectomy catheters, occlusion and perfusion catheters, and biologic patches for vessel and cardiac repair [2] Financial Performance - In Q2 2025, LeMaitre Vascular reported strong growth, particularly in international sales, with Artegraft sales more than doubling quarter-over-quarter outside the U.S. [3] - Analysts project revenue growth of 13-15%, driven by innovative vascular graft products and increasing international penetration [3] Market Position - The company targets niche vascular device markets valued under $200 million, allowing for steady product development with limited competition [4] - LeMaitre Vascular's surgical devices address critical clinical needs, such as bypassing or replacing diseased arteries and improving dialysis access, maintaining relevance in both clinical and commercial settings [4] Product Highlights - Key products include the Artegraft biologic graft and Valvulotomes, which support advanced vascular surgeries [2][5] - The accelerated adoption of biologic grafts like Artegraft, especially in international markets, highlights the company's momentum in advancing vascular surgery solutions [5]